Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 4
2006 4
2007 4
2008 10
2009 8
2010 13
2011 13
2012 12
2013 11
2014 16
2015 14
2016 17
2017 15
2018 15
2019 10
2020 19
2021 17
2022 24
2023 24
2024 25
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Results by year

Filters applied: . Clear all
Page 1
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.
Umemoto K, Sunakawa Y, Ueno M, Furukawa M, Mizuno N, Sudo K, Kawamoto Y, Kajiwara T, Ohtsubo K, Okano N, Matsuhashi N, Itoh S, Matsumoto T, Shimizu S, Otsuru T, Hasegawa H, Okuyama H, Ohama H, Moriwaki T, Ohta T, Odegaard JI, Nakamura Y, Bando H, Yoshino T, Ikeda M, Morizane C. Umemoto K, et al. Among authors: matsumoto t. Br J Cancer. 2023 Apr;128(8):1603-1608. doi: 10.1038/s41416-023-02189-y. Epub 2023 Feb 13. Br J Cancer. 2023. PMID: 36782009 Free PMC article.
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.
Sudo K, Nakamura Y, Ueno M, Furukawa M, Mizuno N, Kawamoto Y, Okano N, Umemoto K, Asagi A, Ozaka M, Ohtsubo K, Shimizu S, Matsuhashi N, Itoh S, Matsumoto T, Satoh T, Okuyama H, Goto M, Hasegawa H, Yamamoto Y, Odegaard JI, Bando H, Yoshino T, Ikeda M, Morizane C. Sudo K, et al. Among authors: matsumoto t. Br J Cancer. 2024 Oct;131(7):1237-1245. doi: 10.1038/s41416-024-02834-0. Epub 2024 Aug 28. Br J Cancer. 2024. PMID: 39198618
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H, Tsuda T, Sunakawa Y, Shimokawa M, Akiyoshi K, Tokunaga S, Shoji H, Kunieda K, Kotaka M, Matsumoto T, Nagata Y, Mizukami T, Mizuki F, Danenberg KD, Boku N, Nakajima TE. Arai H, et al. Among authors: matsumoto t. Cancer Med. 2024 Apr;13(7):e7107. doi: 10.1002/cam4.7107. Cancer Med. 2024. PMID: 38591098 Free PMC article. Clinical Trial.
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, Hirata K, Tsuduki T, Makiyama A, Izawa N, Takahashi N, Tsuda M, Yasui H, Ohta T, Kito Y, Otsu S, Hironaka S, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K. Matsumoto T, et al. Target Oncol. 2024 Mar;19(2):181-190. doi: 10.1007/s11523-024-01043-2. Epub 2024 Mar 1. Target Oncol. 2024. PMID: 38427280 Free PMC article. Clinical Trial.
[The Science of Drug Addiction].
Matsumoto T. Matsumoto T. Brain Nerve. 2024 Jan;76(1):81-87. doi: 10.11477/mf.1416202562. Brain Nerve. 2024. PMID: 38191144 Japanese.
Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
Takahashi N, Hara H, Nagashima K, Hirata K, Masuishi T, Matsumoto T, Kawakami H, Yamazaki K, Hironaka S, Boku N, Muro K. Takahashi N, et al. Among authors: matsumoto t. BMC Cancer. 2023 Aug 5;23(1):726. doi: 10.1186/s12885-023-11199-1. BMC Cancer. 2023. PMID: 37543568 Free PMC article. Clinical Trial.
Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study.
Ikoma T, Matsumoto T, Boku S, Motoki Y, Kinoshita H, Kosaka H, Kaibori M, Inoue K, Sekimoto M, Fujisawa T, Iwai H, Naganuma M, Tanizaki H, Hisamatsu Y, Okada H, Kurata T. Ikoma T, et al. Among authors: matsumoto t. Cancer Immunol Immunother. 2024 May 11;73(7):126. doi: 10.1007/s00262-024-03707-4. Cancer Immunol Immunother. 2024. PMID: 38733406 Free PMC article.
Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study.
Yamamoto Y, Yukami H, Yamaguchi T, Ohori H, Nagasu S, Kagawa Y, Sugimoto N, Sonoda H, Yamazaki K, Takashima A, Okuyama H, Hasegawa H, Kondo C, Baba E, Matsumoto T, Kawamoto Y, Kataoka M, Shindo Y, Ishikawa T, Esaki T, Kito Y, Sato T, Funakoshi T, Yamaguchi T, Shimada Y, Moriwaki T. Yamamoto Y, et al. Among authors: matsumoto t. Int J Clin Oncol. 2024 Dec;29(12):1878-1886. doi: 10.1007/s10147-024-02613-0. Epub 2024 Aug 28. Int J Clin Oncol. 2024. PMID: 39196470
261 results